# US 2019/0324016 A1 · Method for assessing sugar uptake ability of liver

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0324016 A1
- Document ID: US20190324016A1
- Status: Published application
- Kind: A1
- Application number: 16/348,751
- Filed: 2017-11-10
- Published: 2019-10-24
- Earliest claimed: 2016-11-11
- Assignees: Otsuka Pharmaceutical Co., Ltd.; Tohoku University
- Applicants: Otsuka Pharmaceutical Co., Ltd.; Tohoku University
- Inventors: Makoto INADA; Keiko KAWATA; Kimiyoshi SUDOH; Hideki KATAGIRI; Tetsuya YAMADA; Kei TAKAHASHI
- Web page: https://patentgrep.com/patent/US20190324016A1

## CPC

- G01N 33/66: involving blood sugars, e.g. galactose
- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61B 5/0836: {Measuring rate of CO2 production}
- G01N 33/5038: {involving detection of metabolites per se}
- A61B 5/0813: {Measurement of pulmonary parameters by tracers, e.g. radioactive tracers}
- A61K 49/00: Preparations for testing in vivo
- A61K 51/1206: {Administration of radioactive gases, aerosols or breath tests}
- G01N 33/497: of gaseous biological material, e.g. breath
- G01N 33/60: involving radioactive labelled substances
- G01N 2800/042: Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/56: Staging of a disease; Further complications associated with the disease
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

An object of the disclosure is to provide a composition for evaluating the hepatic glucose uptake capacity of a subject and a method for evaluating the hepatic glucose uptake capacity of a subject with the composition. An object of the disclosure is to provide a method for determining the stage of pre-onset diabetes in a subject with pre-onset diabetes using the method for evaluating the hepatic glucose uptake capacity. An aspect of the disclosure accordingly provides a composition comprising 13C-labeled glucose for evaluating the hepatic glucose uptake capacity of a subject. Another aspect of the disclosure provides a method comprising measuring 13C-labeled glucose in a blood sample or an expired air sample obtained from the subject to which the composition was administered. The desired evaluation or determination can be achieved by comparing the measured value with a reference value.

## Claims

### Claim 1

A method of determining the stage of pre-onset diabetes in a subject with pre-onset diabetes, comprising:
(1) measuring the 13C-labeled glucose level in a blood sample obtained from the subject to which 13C-labeled glucose was orally administered; and
(2) comparing the level with a reference value to determine the stage of pre-onset diabetes is stage A or stage B.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the reference value is derived from the levels measured according to step (1) in animals of the same species which have normal hepatic glucose uptake capacities.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the stage is determined to be stage A when the level is lower than the reference value.

### Claim 4 (depends on 3)

The method according to claim 3, wherein stage A is the stage of insulin hypersecretion.

### Claim 5 (depends on 2)

The method according to claim 2, wherein the stage is determined to be stage B when the level is higher than the reference value.

### Claim 6 (depends on 5)

The method according to claim 5, wherein stage B is the stage of decreased hepatic glucose uptake capacity.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the subject is determined to have pre-onset diabetes by a method comprising:
(a) calculating the ratio of the 13CO2 amount to the unlabeled CO2 amount or total CO2 amount in an expired air sample obtained from the subject to which 13C-labeled glucose was orally administered;
(b) comparing the ratio with a reference value to evaluate the ability of the subject to metabolize glucose, wherein the reference value is derived from the ratios calculated according to step (a) in animals of the same species which have normal abilities to metabolize glucose; and
(c) determining that the subject has pre-onset diabetes when the ratio is higher than the reference value.

### Claim 8

A method of evaluating the hepatic glucose uptake capacity of a subject, comprising:
(1) measuring the 13C-labeled glucose level in a blood sample obtained from the subject to which 13C-labeled glucose was orally administered; and
(2) comparing the level with a reference value to evaluate the hepatic glucose uptake capacity.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the reference value is derived from the levels measured according to step (1) in animals of the same species which have normal hepatic glucose uptake capacities.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the subject is determined to have a decreased hepatic glucose uptake capacity when the level is higher than the reference value.

### Claim 11

A method of evaluating the hepatic glucose uptake capacity of a subject, comprising:
(1) calculating the ratio of the 13CO2 amount to the unlabeled CO2 amount or total CO2 amount in an expired air sample obtained from the subject to which 13C-labeled glucose was intravenously administered;
(2) calculating the ratio of the 13CO2 amount to the unlabeled CO2 amount or total CO2 amount in an expired air sample obtained from the subject to which 13C-labeled glucose was orally administered;
(3) calculating the difference between the ratio calculated in step (1) and the ratio calculated in step (2); and
(4) evaluating the hepatic glucose uptake capacity based on the difference calculated in step (3).

### Claim 12 (depends on 11)

The method according to claim 11, wherein step (4) comprises comparing the difference with a reference value, the reference value being derived from the differences calculated according to steps (1) to (3) in animals of the same species which have normal hepatic glucose uptake capacities.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the subject is determined to have a decreased hepatic glucose uptake capacity when the difference is smaller than the reference value.

### Claim 14 (depends on 11)

The method according to claim 11, further comprising calculating the amount of hepatic glucose uptake based on the difference calculated in step (3).

### Claim at position 15

15-18. (canceled)
